With Neşe Önder
Bureaucratic burden and uncertainties caused by lack of sufficient and relevant regulation were blamed by the pharmaceutical industry as one of the significant reasons for the relatively low number of clinical trials conducted in Turkey despite its potential in terms of population, qualified personnel and geographical location.